A vs AEP Stock Comparison

Scores Breakdown

Metric	A	AEP
📈 Growth	18/30	22/30
💰 Profitability	16/20	16/20
🏦 Financial Health	7/20	12/20
💵 Valuation	9/20	14/20
⚠️ Risk (lower is better)	7/10	7/10
Overall Score	53/100	67/100

Side-by-Side Summaries

A Analysis	AEP Analysis
📈 Growth & Financial Trajectory Over eight quarters, Revenues rose from about $1.66B to $1.84B, a positive trend, with a mid-2025 dip. Net income fluctuated from $308M–$434M, ending near $339M in 2026 Q2. The sequence shows top-line resilience but earnings volatility, implying improving mix or cost management but not a steady uplift in profitability. 💰 Margins & Cash Flow Gross Margin is generally in the mid-50s percentile, peaking around 63% in 2024 Q2 and typical ~50–55% in other quarters. Operating Margin has run in the high-teens to low-20s percent range on Revenues of ~$1.6–$1.8B. Operating cash flow remains positive across quarters (roughly $0.27–$0.55B), while investing cash flow is negative (capital outlays), and financing cash flow is often negative, reflecting debt/return actions. 🛡️ Balance Sheet & Liquidity Total Assets (~~$11–$13B) exceed Liabilities (~~$4.8–$6B) with Equity frequently negative, signaling balance-sheet rehabilitation needs. Current assets vs current liabilities suggests solid liquidity (working capital positive); long-term debt remains a meaningful load but generally manageable within cash flows. ⚠️ Key Drivers & Risks Drivers: Life sciences capex & instrument upgrades; continued demand for laboratory testing and automation. Risks: Earnings volatility from cyclic lab-spend; structural negative equity raises valuation sensitivity and balance-sheet risk.	📈 Growth & Financial Trajectory The eight quarters show revenue rising from $5.420B in 2024 Q3 to $6.020B in 2026 Q1, about a net increase of ~11%. Net income fluctuated: from $0.962B at the start to $0.903B at the end, with a peak near $1.288B in 2025 Q2. This signals a healthier top line with episodic earnings swings, ending with higher revenue but a slightly lower cumulative net income than the start. 💰 Margins & Cash Flow Net income margins averaged in the mid-teens, with notable strength around 25% in 2025 Q2. Operating cash flow tended to be positive across quarters, while investing cash flow was typically negative, reflecting ongoing capex. Cash flow from operations generally ranged in the low-to-mid billions, with an indicative average near $1.8B and occasional peaks near $2.5B. 🛡️ Balance Sheet & Liquidity Assets sit in the $110B–$118B range, with liabilities around $76B–$85B and equity roughly $27B–$33B; end-quarter figures show long-term debt near $42B–$50B. The regulated utility profile supports resilience, though leverage remains notable for the sector. ⚠️ Key Drivers & Risks Drivers: regulated rate recovery and ongoing grid modernization investments. Risks: interest-rate sensitivity and regulatory/legislative shifts; earnings volatility driven by weather and macro cycles may affect valuation.

A Analysis

AEP Analysis

📈 Growth & Financial Trajectory

Over eight quarters, Revenues rose from about $1.66B to $1.84B, a positive trend, with a mid-2025 dip. Net income fluctuated from $308M–$434M, ending near $339M in 2026 Q2. The sequence shows top-line resilience but earnings volatility, implying improving mix or cost management but not a steady uplift in profitability.

💰 Margins & Cash Flow

Gross Margin is generally in the mid-50s percentile, peaking around 63% in 2024 Q2 and typical ~50–55% in other quarters.
Operating Margin has run in the high-teens to low-20s percent range on Revenues of ~$1.6–$1.8B.
Operating cash flow remains positive across quarters (roughly $0.27–$0.55B), while investing cash flow is negative (capital outlays), and financing cash flow is often negative, reflecting debt/return actions.

🛡️ Balance Sheet & Liquidity

Total Assets (~~$11–$13B) exceed Liabilities (~~$4.8–$6B) with Equity frequently negative, signaling balance-sheet rehabilitation needs. Current assets vs current liabilities suggests solid liquidity (working capital positive); long-term debt remains a meaningful load but generally manageable within cash flows.

⚠️ Key Drivers & Risks

Drivers: Life sciences capex & instrument upgrades; continued demand for laboratory testing and automation.
Risks: Earnings volatility from cyclic lab-spend; structural negative equity raises valuation sensitivity and balance-sheet risk.

📈 Growth & Financial Trajectory

The eight quarters show revenue rising from $5.420B in 2024 Q3 to $6.020B in 2026 Q1, about a net increase of ~11%. Net income fluctuated: from $0.962B at the start to $0.903B at the end, with a peak near $1.288B in 2025 Q2. This signals a healthier top line with episodic earnings swings, ending with higher revenue but a slightly lower cumulative net income than the start.

💰 Margins & Cash Flow

Net income margins averaged in the mid-teens, with notable strength around 25% in 2025 Q2. Operating cash flow tended to be positive across quarters, while investing cash flow was typically negative, reflecting ongoing capex. Cash flow from operations generally ranged in the low-to-mid billions, with an indicative average near $1.8B and occasional peaks near $2.5B.

🛡️ Balance Sheet & Liquidity

Assets sit in the $110B–$118B range, with liabilities around $76B–$85B and equity roughly $27B–$33B; end-quarter figures show long-term debt near $42B–$50B. The regulated utility profile supports resilience, though leverage remains notable for the sector.

⚠️ Key Drivers & Risks

Drivers: regulated rate recovery and ongoing grid modernization investments.
Risks: interest-rate sensitivity and regulatory/legislative shifts; earnings volatility driven by weather and macro cycles may affect valuation.

Similar Companies

AMAT Score: 80 AME Score: 81 ANET Score: 84 GOOGL Score: 78 TMO Score: 75 WAT Score: 78

Top Rated Companies

View Top 20 →

MU "MICRON TECHNOLOGY INC"

AVGO "Broadcom Inc."

KMI "KINDER MORGAN, INC."

MNST "Monster Beverage Corp"

NEM "NEWMONT Corp /DE/"